XOFIGO FDA APPROVED
Posted on: 04/29/2015
Xofigo (Alpharadin - Radium 233) is now FDA approved and available through our physicians Stephen M. Eulau, M.D. and Robert K. Takamiya, M.D. at Swedish Cancer Institute (206) 386-2323.
Xofigio represents the latest injectable radiation therapy with survival advantages in patients with hormone refractory prostate cancer with bone mets.
Visit our PCa COMMENTARY Vol 83 September - October 2013 for more information.
For details and scheduling call the Swedish Cancer Institute (206) 386-2323.
Back to articleIn This Section
